Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
BMJ Open
|
March 26, 2025
Is sports-branded screening effective in identifying adults at greatest risk of developing cardiovascular disease: a convergent parallel mixed-methods design to identify adults at greatest risk of developing cardiovascular disease using an opportunistic sports-branded health screening approach in the community
Ian David Jones, Deborah Fitzsimmons, Massirfufulay Kpehe Musa, et al.
Molecular Microbiology
|
November 23, 2013
An early cytoplasmic step of peptidoglycan synthesis is associated to MreB in Bacillus subtilis
Anne-Stéphanie Rueff, Arnaud Chastanet, Julia Domínguez-Escobar, et al.
BMJ Open
|
February 10, 2024
Manchester Intermittent Diet in Gestational Diabetes Acceptability Study (MIDDAS-GDM): a two-arm randomised feasibility protocol trial of an intermittent low-energy diet (ILED) in women with gestational diabetes and obesity in Greater Manchester
Elizabeth Dapre, Basil G Issa, Michelle Harvie, et al.
Progress in Cardiovascular Diseases
|
January 24, 2023
Cardiovascular disease prevention and management in the COVID-19 era and beyond: An international perspective
Mark A Faghy, James Yates, Andrew P Hills, et al.
Plos One
|
September 28, 2023
Protocol for a cluster randomised waitlist-controlled trial of a goal-based behaviour change intervention for employees in workplaces enrolled in health and wellbeing initiatives
Lailah Alidu, Lena Al-Khudairy, Ila Bharatan, et al.
International Journal of Environmental Research and Public Health
|
April 16, 2025
A Mixed-Methods Cluster Randomised Waitlist-Controlled Trial of a Goal-Based Behaviour Change Intervention Implemented in Workplaces
Laura Kudrna, James Yates, Lailah Alidu, et al.
Cancer Chemotherapy and Pharmacology
|
March 16, 2018
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
Emma Dean, Udai Banerji, Jan H M Schellens, et al.
Molecular Cancer Therapeutics
|
February 2, 2012
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background
Barry R Davies, Hannah Greenwood, Phillippa Dudley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 5, 2022
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Giuditta Illuzzi, Anna D Staniszewska, Sonja J Gill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers
Udai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
BMJ Open
|
March 26, 2025
Is sports-branded screening effective in identifying adults at greatest risk of developing cardiovascular disease: a convergent parallel mixed-methods design to identify adults at greatest risk of developing cardiovascular disease using an opportunistic sports-branded health screening approach in the community
Ian David Jones, Deborah Fitzsimmons, Massirfufulay Kpehe Musa, et al.
Molecular Microbiology
|
November 23, 2013
An early cytoplasmic step of peptidoglycan synthesis is associated to MreB in Bacillus subtilis
Anne-Stéphanie Rueff, Arnaud Chastanet, Julia Domínguez-Escobar, et al.
BMJ Open
|
February 10, 2024
Manchester Intermittent Diet in Gestational Diabetes Acceptability Study (MIDDAS-GDM): a two-arm randomised feasibility protocol trial of an intermittent low-energy diet (ILED) in women with gestational diabetes and obesity in Greater Manchester
Elizabeth Dapre, Basil G Issa, Michelle Harvie, et al.
Progress in Cardiovascular Diseases
|
January 24, 2023
Cardiovascular disease prevention and management in the COVID-19 era and beyond: An international perspective
Mark A Faghy, James Yates, Andrew P Hills, et al.
Plos One
|
September 28, 2023
Protocol for a cluster randomised waitlist-controlled trial of a goal-based behaviour change intervention for employees in workplaces enrolled in health and wellbeing initiatives
Lailah Alidu, Lena Al-Khudairy, Ila Bharatan, et al.
International Journal of Environmental Research and Public Health
|
April 16, 2025
A Mixed-Methods Cluster Randomised Waitlist-Controlled Trial of a Goal-Based Behaviour Change Intervention Implemented in Workplaces
Laura Kudrna, James Yates, Lailah Alidu, et al.
Cancer Chemotherapy and Pharmacology
|
March 16, 2018
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
Emma Dean, Udai Banerji, Jan H M Schellens, et al.
Molecular Cancer Therapeutics
|
February 2, 2012
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background
Barry R Davies, Hannah Greenwood, Phillippa Dudley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 5, 2022
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Giuditta Illuzzi, Anna D Staniszewska, Sonja J Gill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers
Udai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, et al.
Page
of 6